Depletion of complement system immunity in patients with myocardial infarction

WENWEN YAN1, LIN CHE1, JINFA JIANG1, FAN YANG2, QIANGLIN DUAN1, HAOMING SONG1, XIAOHONG LIU1, YUQIN SHEN1 and LEMIN WANG1

Departments of 1Cardiology and 2Laboratory Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China

Received September 22, 2015; Accepted October 11, 2016

DOI: 10.3892/mmr.2016.5912

Abstract. The aim of the present study was to evaluate differences in the expression of complement system genes, and serum levels of CH50, C3 and C4 in peripheral blood mononuclear cells from patients with myocardial infarction (AMI), stable angina pectoris (SA) and controls. A total of 100 patients with AMI, 100 with SA and 100 clinical controls were recruited in the present study. In each group, 20 randomly selected individuals were examined using whole human genome microarray analysis to detect the expression of genes of the complement system. The serum levels of CH50, C3 and C4 were measured in all 300 subjects. In the patients with AMI, the expression levels of genes encoding C1qα, C1qβ, C1r, C1r, Factor P, C5a (complement component), CR1, integrin αM, integrin αX, integrin β2, C5aR, CR1g (complement receptors) and CD46, CD55 and CD59 (complement regulators) were significantly higher, compared with the respective genes in the SA patients and controls (P<0.05), whereas the mRNA levels of C1s, C7, C8β and C9 were the lowest in this group (P<0.05). No statistically significant differences were found in the gene expression levels of complement components or regulators between the SA and control groups. The serum levels of CH50, C3 and C4 were significantly increased in the AMI and SA groups, compared with the controls. In the AMI and SA groups, the complement system was activated. However, the differential mRNA expression of complement components, receptors and regulators in the AMI group suggested the dysfunction of the C5b-9 complex. The depression of complement system immunity in the patients with AMI may be associated with the pathogenesis of AMI.

Introduction

Coronary atherosclerotic diseases (CADs) are a leading contributor to morbidity and mortality rates in the modern world, and there is increasing evidence that atherosclerosis is a chronic inflammatory disease (1). However, previous data obtained from animal models and clinical studies have suggested that the complement system is important in the pathogenesis of CADs, and is also involved in the progression of inflammation and thrombosis (2-5).

The complement system is an innate cytotoxic host defense system, which normally functions to eliminate foreign pathogens and self-particles, and can be activated via three mechanisms, termed the classical, lectin or alternative pathways. The initiation of each pathway eventually results in the formation of the terminal C5b-9 complex, or the membrane attack complex (MAC), which is primarily responsible for cell lysis (6). Activation of the complement system also results in the production of numerous effector molecules with potent biological activities, including complement-mediated opsonization and phagocytosis by C3b, C4b and ic3b, recognized by complement receptors, and anaphylatoxin production through C3a, C4a and C5a (7).

According to the results of clinical studies, monomeric C-reactive protein, myocardial necrosis and apoptotic cells may serve as potent activators of the complement system (8-10). However, the extent of activation of the complement system in different forms in CAD remain to be fully elucidate. For stable angina pectoris (SA) in particular, a limited number of studies have been performed, the majority of which have produced controversial results (11-14). The complement system is composed of >30 proteins, including complement components, receptors and regulators, which act to generate immunoprotective and proinflammatory products. In the present study, human microarray analysis was used to systematically examine the mRNA expression levels of all complement components, receptors and regulators in peripheral blood mononuclear cells (PBMCs) isolated from patients with acute myocardial infarction (AMI), those with SA and clinical controls. The serum levels of CH50, C3 and C4 were also measured in all 300 subjects. The aim of the present in vitro study was to investigate the nature of complement system immunity in the AMI and SA stages of CAD.

Correspondence to: Dr Yuqin Shen or Dr Lemin Wang, Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Putuo, Shanghai 200065, P.R. China
E-mail: wanglemin@tongji.edu.cn
E-mail: sy_1963@126.com

Key words: myocardial infarction, stable angina pectoris, complement immunity, gene expression
Materials and methods

Patient information. The present study recruited 100 patients with AMI, 100 patients with SA and 100 clinical controls. Human microarray analysis was performed in 60 individuals, which were randomly selected from the AMI, SA and control groups (20 in each group). The sample sizes, the number of subjects per group, were based on an assumed within-group variance of 0.50 and targeted nominal power of 0.95 (15). The baseline demographic data is shown in Table I. The patients with AMI were admitted ≤2 h following onset of symptoms to the Coronary Care Unit (Tongji Hospital, Shanghai, China) between January and December 2013, and included 88 men and 12 women, with an age of 59±13 years (mean ± standard deviation). The SA group contained 100 patients (82 men and 18 women aged 63±10 years). As a control group, 100 clinical inpatients (80 men and 20 women aged 61±7 years) were enrolled during the same period. Histories, physical examination, ECG, chest radiography and routine chemical analyses confirmed the controls had no evidence of CAD.

All patients with AMI were diagnosed on the basis of the following criteria (16): Detection of an increase in cardiac biomarker values, preferably cardiac troponin, with at least one value above the 99th percentile upper reference limit and with at least one of the following: i) Symptoms of ischemia; ii) new or presumed new significant ST-segment-T wave changes or new left bundle branch block; iii) development of pathological Q waves on ECG; iv) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; v) identification of an intracoronary thrombus on angiography.

All patients with SA had exclusively effort angina with a positive exercise stress test and at least one coronary stenosis detected on angiography (>70% reduction in lumen diameter).

No significant differences were present among the three groups in terms of age, gender, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides and fasting plasma glucose.

The exclusion criteria for the three groups were as follows: Venous thrombosis, history of severe renal or hepatic diseases, hematological disorders, acute or chronic inflammatory diseases and malignancy.

The experimental protocol was approved by the ethics committee of Tongji University (Shanghai, China) and informed consent was obtained.

Gene expression chips. Agilent G4112F Whole Human Genome Oligo Microarrays, purchased from Agilent Technologies, Inc. (Santa Clara, CA, USA) were used in the chip analysis. A microarray was composed of >41,000 genes or transcripts, including targeted 19,596 entrez gene RNAs. The sequence information used in the microarrays was derived from the latest RefSeq (ncbi.nlm.nih.gov/refseq/), Goldenpath (genekws.com/33-steps-resources-wheel/), Ensembl (asia.ensembl.org/index.html) and Unigene (ncbi.nlm.nih.gov/unigene) databases (17). The functions of >70% of the genes in the microarray were already known. A total of 60 randomly selected patients were subjected to the chip analysis (20 in each group).

Total RNA isolation. Peripheral blood samples (10 ml) from the median cubital vein were drawn from all patients using a PAXgene™ tube immediately following admission. Of each blood sample, 5 ml was used for total RNA isolation, and the remainder was used for the detection of CH50, C3 and C4. Leucocytes were obtained through density gradient centrifugation at 3,000 x g for 15 min at 4°C with Ficoll solution, and the remaining red blood cells were destroyed using erythrocyte lysis buffer (Qiagen GmbH, Hilden, Germany). Total RNA was extracted and purified using a PAXgene™ Blood RNA kit (cat. no. 762174; Qiagen GmbH) following the manufacturer’s protocol. It was further assessed for an RNA integrity number (RIN) to inspect RNA integration using an Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). The sample was considered qualified when the 2100 RIN and 28S/18S were ≥0.7.

RNA amplification and labeling. RNA quantity was detected using a Nanodrop. The total RNA was amplified using a reverse transcription kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and labeled using a Low Input Quick Amp labeling kit, One-Color (cat. no. 5190-2305; Agilent Technologies, Inc.), following the manufacturer’s protocol. The Labeled cRNA was purified using an RNeasy mini kit (cat. no. 74,106; Qiagen GmbH).

Microarray hybridization. Each slide was hybridized with 1.65 µg Cy3-labeled cRNA using a Gene Expression Hybridization Kit (cat. no. 5188-5242; Agilent Technologies, Inc.) in a hybridization oven (cat. no. G2545A; Agilent Technologies, Inc.), following the manufacturer’s protocol. After 17 h of hybridization, the slides were washed in staining dishes (cat. no. 121; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with a Gene Expression Wash Buffer kit (cat. no. 5188-5327; Agilent Technologies, Inc.), according to the manufacturer’s protocol.

Chip scan and data acquisition. The slides were scanned using an Agilent Microarray Scanner (cat. no. G2565CA; Agilent Technologies, Inc.) with the following default settings: Dye channel, green; scan resolution, 3 µm; 20 bit. Data were extracted using Feature Extraction 10.7 software (Agilent Technologies, Inc.). The raw data were normalized using the Quantile algorithm with GeneSpring 11.0 software (Agilent Technologies, Inc.).

Reverse transcription-quantitative polymerase chain reaction RT-qPCR analysis. The spots in the microarray were randomly selected and their expression levels were confirmed using RT-qPCR analysis. Among all the genes with differential expression, three genes were randomly selected and subjected to RT-qPCR analysis, in addition to the housekeeping gene, GAPDH. The following RNA/primer mixture was prepared in each tube: Total RNA 5 µg, random hexamers (50 ng/µl) 3 µl, 10 mM dNTP mix 1 µl and DEPC H2O to 10 µl. The samples were then incubated at 65°C for 5 min and then on ice for at least 1 min. Next, the reaction master mixture was prepared. For each reaction, the components were as follows: 10 x RT buffer 2 µl, 25 mM MgCl2, 4 µl, 0.1 M DTT 2 µl and RNAaseOUT 1 µl. The reaction mixture was added...
to the RNA/primer mixture was mixed briefly, and then placed at room temperature for 2 min. Next, 1 µl (50 U) of SuperScript II RT was added to each tube, mixed and incubated at 25˚C for 10 min. The tubes were then incubated at 42˚C for 50 min, heat inactivated at 70˚C for 15 min, and chilled on ice. Then, 1 µl RNase H was added and incubated at 37˚C for 20 min. The 1st strand cDNA was stored at ‑20˚C until. PCR thermocycling conditions were as follows: 50˚C 2 min, 1 cycle, 95˚C for 10 min 1 cycle, 95˚C for 15 sec, 60˚C for 30 sec, 72˚C for 30 sec, 40 cycles and 72˚C for 10 min, 1 cycle. The relative expression was indicated as the expression of the target gene normalized to the expression of GAPDH (2^ΔΔCq). Melting curve analysis and the 2^ΔΔCq method (18) were used to detect differences in the levels of expression among the three groups. The results from the RT-qPCR analysis were consistent with the microarray analysis.

Laboratory assays. The remaining 5 ml blood sample was centrifuged at 3,000 x g for 15 min at 4˚C within 1 h to obtain the serum. Following collection, the tubes were placed on ice in order to avoid complement inactivation, followed by immediate analyses. CH50 was detected using a liposome immune assay on a Beckman DxC-800 fully automatic biochemical analyzer (Beckman Coulter, Inc., Brea, CA, USA; reagents from Wako Pure Chemical Industries, Ltd., Osaka, Japan). C3 and C4 were detected using immunonephelometry (BNII system; Siemens AG, Munich, Germany; reagents, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). The reference intervals were as follows: CH50, 23-46%; C3, 0.9-1.8% and C4, 0.1-0.4%.

Statistical analysis. Descriptive statistical data are expressed as the mean ± standard deviation. Differences between groups were examined using one-way analysis of variance, following which all pairwise group mean comparisons were performed using Tukey’s method. Density curves for CH50, C3 and C4

<table>
<thead>
<tr>
<th>Index</th>
<th>AMI (n=100)</th>
<th>SA (n=100)</th>
<th>Con (n=100)</th>
<th>Total</th>
<th>AMI, vs. SA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>58.6±12.7</td>
<td>63.6±11.1</td>
<td>61.1 ± 7.4</td>
<td>0.542</td>
<td>0.211</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>88/12</td>
<td>82/18</td>
<td>80/20</td>
<td>0.16</td>
<td>0.08</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.6±2.9</td>
<td>22.5±2.2</td>
<td>22.7±1.9</td>
<td>0.112</td>
<td>0.76</td>
</tr>
<tr>
<td>Ethnicity, Han</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tobacco (no./day)</td>
<td>13.8±10.4</td>
<td>12.4±8.6</td>
<td>11.2±8.1</td>
<td>0.134</td>
<td>0.448</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>130±11</td>
<td>123±10</td>
<td>122±7</td>
<td>0.147</td>
<td>0.721</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>67±9</td>
<td>72.0±9</td>
<td>77±4</td>
<td>0.121</td>
<td>0.094</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>2.2±1.3</td>
<td>2.3±1.7</td>
<td>2.6±1.5</td>
<td>0.123</td>
<td>0.576</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.4±1.6</td>
<td>1.6±1.1</td>
<td>1.7±0.8</td>
<td>0.22</td>
<td>0.132</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>0.7±0.9</td>
<td>0.8±0.6</td>
<td>1.0±0.2</td>
<td>0.067</td>
<td>0.103</td>
</tr>
<tr>
<td>FBG (mmol/l)</td>
<td>5.4±0.1</td>
<td>5.3±0.9</td>
<td>5.1±0.2</td>
<td>0.094</td>
<td>0.334</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting plasma glucose; AMI, acute myocardial infarction; SA, stable angina pectoris; Con, control.

Figure 1. mRNA expression of complement components. (A) Early and (B) late complement components in peripheral blood mononuclear cells. *=P<0.05 and **=P<0.01 among the three groups; *P<0.05 and **P<0.01 AMI, vs. Con; *P<0.05 and **P<0.01 AMI, vs. SA. AMI, acute myocardial infarction; SA, stable angina pectoris; Con, control.
were delineated using R version 3.1.3 software (r-project.org). Data were analyzed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Gene expression of complement components. The results showed that early complement components, including C1qa, C1qb, C1qγ, C1r, C1s, C2, C3, C4b, Factor B, Factor D, Factor P, MBL, MASP1, and MASP2 were expressed in the PBMCs from the three groups of patients (Fig. 1A). In the PBMCs from the three groups, the expression levels of genes encoding C1qa, C1qb, C1qγ, C1r, Factor P and C1s were significantly different (P<0.05). In the AMI group, the gene expression levels of C1qa (P<0.05), C1qb, C1qγ, C1r and Factor P (all P<0.01), were significantly upregulated, compared with those in the SA group and control group, respectively, whereas the mRNA expression of C1s in the AMI group was downregulated (P<0.05), compared with that in the control group. The gene expression levels of MBL, MASP1 and MASP2 were lowest in the AMI group among the three groups.

The gene expression levels of late complement components, including C5α, C6, C7, C8α, C8β, C8γ and C9, were also examined in the PBMCs from the three groups (Fig. 1B). In the AMI group, the mRNA expression of C5α was significantly upregulated (P<0.01), whereas the expression levels of C7, C8β and C9 were significantly downregulated, compared with those in the SA and control groups, respectively (P<0.05). However, no significant differences were found in the mRNA expression of early or late complement components between the SA and control groups.

Table II. Levels of CH50, C3 and C4 among the AMI, SA and Con groups.

<table>
<thead>
<tr>
<th>Index</th>
<th>AMI (%; n=100)</th>
<th>SA (%; n=100)</th>
<th>Con (%; n=100)</th>
<th>Total</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH50</td>
<td>46.60±0.77</td>
<td>43.10±0.70</td>
<td>34.10±0.52</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>C3</td>
<td>1.46±0.47</td>
<td>1.40±0.38</td>
<td>1.27±0.27</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>C4</td>
<td>0.27±0.05</td>
<td>0.26±0.05</td>
<td>0.24±0.07</td>
<td>&lt;0.001</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation. AMI, acute myocardial infarction; SA, stable angina pectoris; Con, control.
Gene expression of complement receptors. The mRNA expression of complement receptors, including CR1, CR2, C3aR, integrin αM, integrin αX, integrin β2, C5aR and CR1g were also examined in the PBMCs from the three groups (Fig. 2A). CR3 consists of integrin αM and integrin β2, and CR4 comprises integrin αX and integrin β2. In the PBMCs from the three groups, the expression levels of the genes encoding CR1, CR2, integrin αM, integrin αX, integrin β2, C5aR and CR1g were significantly different (P<0.01). In the AMI group, the mRNA expression levels of CR1, integrin αM, integrin αX, integrin β2, C5aR and CR1g were significantly higher, compared with those in the SA and control groups (P<0.05). The mRNA expression of CR2 was significantly downregulated in the AMI and SA groups, compared with that in the control group (P<0.01).

Gene expression of complement regulators. The gene expression levels of complement regulators, including C1 inhibitory factor (C1INH), C4b binding protein α (C4bα), C4b binding protein β (C4bβ), Factor I, Factor H, Factor H-related protein 1 (CFHR-1), CD46 (MCP), CD55 (DAF), vitronectin (VTN), clusterin (CLU) and CD59 (MIRL) were detected
in PBMCs from the three groups of patients (Fig. 2B). The mRNA levels of CD46, CD55 and CD59 were significantly different among the three groups (P<0.01). In the PBMCs from the AMI group, the expression levels of genes encoding CD46, CD55 and CD59 were significantly higher, compared with those in the other two groups (P<0.01). No significant differences were found in the gene expression of complement regulators between the SA and control groups.

**Serializer levels of complement components.** The serum levels of CH50, C3 and C4 were significantly increased in the AMI and SA groups, compared with the control group (Table II). The level of CH50 in the AMI group was higher, compared with that in the SA group (P<0.01). No significant differences were found between the AMI and SA groups in the levels of C3 or C4. The density curves of CH50, C3 and C4 are shown in Fig. 3A-C.

**Discussion**

In the present study, the early complement components of three complement pathways were examined, and it was found that the mRNA levels of C1q, C1q, C1q and C1r were significantly upregulated in patients with AMI, compared with patients with SA patients and controls (Fig. 1). The upregulation of the mRNA levels of C1q, C1q, C1q and C1r suggested that the classical pathway, which is typically initiated by IgM or IgG-antibody/antigen immune complexes, was activated in the patients with AMI (19). The alternative pathway is activated predominantly by ‘foreign surfaces’, through factor P and the spontaneous hydrolysis of C3-C3b. In the present study, the expression of factor P in the AMI group was significantly higher, compared with the other two groups, indicating that the alternative pathway may also have been activated. The activation of the classical and alternative pathways in the present study was consistent with the results from previous clinical studies (10,11,19). When mannose-bind lectin (MBL) or ficolin bind to carbohydrate on the surface of a pathogen, the MBL-associated serine proteases (MASPs) are activated, following which then the lectin pathway is activated (20). Previous studies have shown that individuals with MBL and MBL-associated MASP deficiencies have immune dysfunction and are susceptible to exotic pathogens (21-24). In the present study, the gene expression levels of MBL, MASP1 and MASP2 were lowest in the patients with AMI among the three groups, therefore, the downregulated expression of these three genes indicated decreased lectin pathway activity in the AMI group.

Three distinct pathways share a common terminal access to form the C5b-9 complex (MAC), which forms a transmembrane pore in the target cell membrane that causes cell lysis and death. C5b initiates the formation of the MAC, which consists of C5b, C6, C7, C8 and multiple molecules of C9. In the results of the present study, the expression of seven late complement component genes was detected, and five of these, including the C7, C6, C6, C8 and C9 mRNAs were lowest in the patients with AMI. The significant decline in the gene expression levels of C7, C8 and C9 in patients with AMI may inhibit MAC formation.

The present study also examined the gene expression levels of eight complement receptors (Fig. 2A), and the mRNA levels of CR1, CR3, CR4, C5aR and CR1g were significantly higher in the AMI group among the three groups. This suggested that the interactions between certain complement effector molecules, including C3b, C4b, iC3b, C3d and C3c, and their receptors were enhanced, and that the complement effectors were involved in opsonization and phagocytosis, also promoted the mobilization, migration and proliferation of leukocytes. The mRNA expression levels of CR2 in the AMI and SA groups were significantly downregulated, compared with the control group. CR2 is a B cell membrane glycoprotein, which is involved in B cell activation, survival and proliferation. In addition, CR2 is important in the recognition of foreign DNA from bacterium, viruses and other pathogens during host-immune responses (25,26). In the present study the gene expression levels of CR2 were significantly downregulated in the AMI and SA groups, suggesting possible immune dysfunction in the B cells, and the potential increased risk of infections in patients with AMI and SA.

The gene expression levels of eleven complement regulators were also detected in the present study (Fig. 2B). The results showed that the mRNA expression levels of CD46, CD55 and CD59 were significantly upregulated in the AMI group. CD46, a known cofactor protein, acts as a cofactor for factor I in the degradation of C3b and C4b, and inhibits convertase formation. CD55, a decay accelerating factor, prevents the formation of new C3 and C5 convertases and accelerates the decay of preformed C3 and C5 convertases. CR1 belongs to the regulators of complement activation protein family, and exhibits CD46 and CD55 activities (27). CD59 is a key regulator of MAC assembly and restricts the formation of MAC (28-30). The upregulated gene expression levels of CR1, CD46, CD55 and CD59 in the patients with AMI suggested the inhibition of MAC formation.

The plasma levels of CH50, C3 and C4, which reflect the activities of C1-C9 via the classical pathway, were all elevated in the AMI and SA groups. By analyzing the levels of genes and proteins in the present study, complement was found to be activated in the AMI and SA patient groups. However, the differential mRNA expression of complement components, receptors and regulators in AMI suggested that the inhibition of the C5b-9 complex induced cell lysis. The depression of cytolytic effects in the complement system in patients with AMI may be associated with the pathogenesis of AMI. As a consequence, improving complement-mediated innate immunity may be considered as a potential target for medical interventions in patients with AMI.

**Acknowledgements**

This study was supported by the Shanghai Traditional Chinese Medicine 3-year Development Program (grant no. 2014-2016), the Shanghai Health Bureau (grant no. 2014Y0046) and the National Natural Science Fund (grant no. 81570359).

**References**


